Deep vein thrombosis cost-effectiveness of therapy
Editor(s)-In-Chief: The APEX Trial Investigators, C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Cafer Zorkun, M.D., Ph.D. [2] Ujjwal Rastogi, MBBS [3]; Kashish Goel, M.D.; Assistant Editor(s)-In-Chief: Justine Cadet
|
Deep Vein Thrombosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Special Scenario |
|
Trials |
|
Case Studies |
|
Deep vein thrombosis cost-effectiveness of therapy On the Web |
|
Deep vein thrombosis cost-effectiveness of therapy in the news |
|
Risk calculators and risk factors for Deep vein thrombosis cost-effectiveness of therapy |
Overview
In United States, deep vein thrombosis DVT and pulmonary embolism PE costs are[1]:
- Initial hospitalization, average more than $9,800 and $14,000 respectively;
- Rehospitalization (over half of which occurs within 90 days) costs average more than $11,800 and $14,700, respectively.
Thus, after major orthopedic surgery, the use of effective VTE prevention strategies can reduce this economic burden.
On the basis of Canadian cost-effectiveness guidelines in the early 1990s, there is moderate to strong evidence to adopt enoxaparin prophylaxis against DVT after total hip replacement.[2]
References
- ↑ Spyropoulos AC, Lin J (2007). "Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations". J Manag Care Pharm. 13 (6): 475–86. PMID 17672809.
- ↑ O'Brien BJ, Anderson DR, Goeree R (1994). "Cost-effectiveness of enoxaparin versus warfarin prophylaxis against deep-vein thrombosis after total hip replacement". CMAJ. 150 (7): 1083–90. PMC 1486381. PMID 8137188. Unknown parameter
|month=ignored (help)